論文 - 盛武 浩
-
プロプラノロールが著効した耳下腺部乳児血管腫の２例 査読あり
下之段秀美、原田雅子、木下真理子、澤 大介、児嶋ひとみ、上村幸代、盛武 浩、松田圭三、布井博幸
宮崎県医師会雑誌 38 ( 2 ) 110 - 114 2014年9月
記述言語：日本語 掲載種別：症例報告
-
Sakaguchi H., Nishio N., Hama A., Kawashima N., Wang X., Narita A., Doisaki S., Xu Y., Muramatsu H., Yoshida N., Takahashi Y., Kudo K., Moritake H., Nakamura K., Kobayashi R., Ito E., Yabe H., Ohga S., Ohara A., Kojima S.
Haematologica 99 ( 8 ) 1312 - 1316 2014年8月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Haematologica
Predicting the response to immunosuppressive therapy could provide useful information to help the clinician define treatment strategies for patients with aplastic anemia. In our current study, we evaluated the relationship between telomere length of lymphocytes at diagnosis and the response to immunosuppressive therapy in 64 children with aplastic anemia, using flow fluorescence in situ hybridization. Median age of patients was ten years (range 1.5-16.2 years). Severity of the disease was classified as very severe in 23, severe in 21, and moderate in 20 patients. All patients were enrolled in multicenter studies using antithymocyte globulin and cyclosporine. The response rate to immunosuppressive therapy at six months was 52% (33 of 64). The probability of 5-year failure-free survival and overall survival were 56% (95% confidence interval (CI): 41-69%) and 97% (95%CI: 87-99%), respectively. Median telomere length in responders was -0.4 standard deviation (SD) (-2.7 to +3.0 SD) and -1.5 SD (-4.0 to +1.6 (SD)) in non-responders (P < 0.001). Multivariate analysis showed that telomere length shorter than -1.0 SD (hazard ratio (HR): 22.0; 95%CI: 4.19-115; P < 0.001), platelet count at diagnosis less than 25×10 9 /L (HR: 13.9; 95%CI: 2.00-96.1; P=0.008), and interval from diagnosis to immunosuppressive therapy longer than 25 days (HR: 4.81; 95%CI: 1.15-20.1; P=0.031) were the significant variables for poor response to immunosuppressive therapy. Conversely to what has been found in adult patients, measurement of the telomere length of lymphocytes at diagnosis is a promising assay in predicting the response to immunosuppressive therapy in children with aplastic anemia. © 2014 Ferrata Storti Foundation.
-
Nakayama H., Tabuchi K., Tawa A., Tsukimoto I., Tsuchida M., Morimoto A., Yabe H., Horibe K., Hanada R., Imaizumi M., Hayashi Y., Hamamoto K., Kobayashi R., Kudo K., Shimada A., Miyamura T., Moritake H., Tomizawa D., Taga T., Adachi S.
International Journal of Hematology 100 ( 2 ) 171 - 179 2014年8月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Hematology
The outcomes of children with relapsed acute myeloid leukemia (AML) are known to be poor, but remain obscure. We retrospectively analyzed 71 patients who had relapsed following first-line treatment under the AML99 protocol. We investigated the time and site of recurrence, response to re-induction therapy, and performance of hematopoietic stem cell transplantation (HSCT) in relapsed cases, and performed a multivariate analysis to identify prognostic factors. The 5-year overall-survival (OS) rate after relapse was 37 %. Of 71 patients, three died without any anti-leukemic therapy and two underwent allogeneic HSCT. The remaining 66 patients received re-induction chemotherapy, and 33 (50 %) achieved second CR (CR2). Twenty-two of 25 (88 %) late relapse patients and 11 of 41 (27 %) early relapse patients achieved CR2 (P < 0.001). Twenty-nine CR2 cases and 35 non-CR2 cases underwent allogeneic HSCT. The 5-year OS rate was significantly higher in patients who underwent HSCT in CR2 than those in non-CR2 (66 vs. 17 %, P < 0.000001). Multivariate analysis indicated that early relapse (P < 0.05) and the positivity of the FMS-like tyrosine kinase 3-internal tandem duplication (P < 0.05) were adverse prognostic factors for survival. In conclusion, the etiology of relapsed pediatric AML needs to be elucidated and effective chemotherapy should be administered to obtain CR2. © 2014 The Japanese Society of Hematology.
-
Clinical characteristics and genetic analysis of childhood acute lymphoblastic leukemia with hemophagocytic lymphohistiocytosis: A Japanese retrospective study by the Kyushu-Yamaguchi Children’s Cancer Study Group. 査読あり
Moritake H, Kamimura S, Nunoi H, Nakayama H, Suminoe A, Inada H, Inagaki J, Yanai F, Okamoto Y, Shinkoda Y, Shimomura M, Itonaga N, Hotta N, Hidaka Y, Ohara O, Yanagimachi M, Nakajima N, Okamura J, Kawano Y
Int J Hematol 2014年7月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Andoh T., Fujimoto T., Sudo T., Suzuki M., Sakurai Y., Sakuma T., Moritake H., Sugimoto T., Takeuchi T., Sonobe H., Epstein A., Fukumori Y., Ono K., Ichikawa H.
Applied Radiation and Isotopes 88 59 - 63 2014年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Applied Radiation and Isotopes
Clear cell sarcoma (CCS) is a rare malignant tumor with a poor prognosis. In our previous study, the tumor disappeared under boron neutron capture therapy (BNCT) on subcutaneously-transplanted CCS-bearing animals. In the present study, the tumor disappeared under this therapy on model mice intramuscularly implanted with three different human CCS cells. BNCT led to the suppression of tumor-growth in each of the different model mice, suggesting its potentiality as an alternative to, or integrative option for, the treatment of CCS. © 2013 Elsevier Ltd.
-
Kawano N., Tasaki A., Kuriyama T., Tahara Y., Yoshida S., Ono N., Himeji D., Yamashita K., Shibata Y., Goto T., Inoue T., Yokota-Ikeda N., Uezono S., Yuge A., Nishiguchi T., Kinjo T., Ogura Y., Beppu K., Ueda Y., Kinoshita M., Moritake H., Shimoda K., Ochiai H., Ueda A.
Internal Medicine 53 ( 3 ) 205 - 213 2014年2月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Internal Medicine
Objective Disseminated intravascular coagulation (DIC) is a clinical condition with high mortality that is characterized by the systemic activation of coagulation pathways resulting in multiple organ failure. Although no standard treatment for DIC has been established, recent reports have indicated that recombinant human soluble thrombomodulin (rTM) is effective against DIC. Methods To elucidate the clinical characteristics and outcomes of DIC, we retrospectively analyzed 92 DIC patients who were treated with rTM at Miyazaki Prefectural Hospital over a 4-year period (62 patients had infectious diseases and 30 patients had hematological diseases). A diagnosis of DIC was made based on the diagnostic criteria of the Japanese Association for Acute Medicine (JAAM) and Japanese Ministry of Health and Welfare (JMHW) for infectious diseases and hematological diseases, respectively. In addition to treating the underlying disease, rTM was administered for six consecutive days. Results In this study, 49 of the 92 DIC patients (53.3%) experienced resolution of DIC seven days after administration (46.8% patients with infectious disease and 66.7% with hematological disease). A higher survival rate was observed after a 28-day observation period in 69 of the 92 patients (75.0%) (72.6% of the patients with infectious disease and 80.0% of the patients with hematological disease). A lower DIC score at the initiation of rTM treatment was closely related to a higher rate of resolution of DIC. Conclusion Our findings indicate that rTM therapy is an effective, safe and feasible treatment for DIC patients. Furthermore, making an accurate and early diagnosis of DIC and providing subsequent immediate treatment with rTM may improve the resolution of DIC. © 2014 The Japanese Society of Internal Medicine.
-
Clinical characteristics and genetic analysis of childhood acute lymphoblastic leukemia with hemophagocytic lymphohistiocytosis: a Japanese retrospective study by the Kyushu-Yamaguchi Children's Cancer Study Group 査読あり
Hiroshi Moritake 1, Sachiyo Kamimura, Hiroyuki Nunoi, Hideki Nakayama, Aiko Suminoe, Hiroko Inada, Jiro Inagaki, Fumio Yanai, Yasuhiro Okamoto, Yuichi Shinkoda, Maiko Shimomura, Nobuyoshi Itonaga, Noriko Hotta, Yasufumi Hidaka, Osamu Ohara, Masakatsu Yanagimachi, Noriko Nakajima, Jun Okamura, Yoshifumi Kawano
Int J Hematol 2014年1月
担当区分：筆頭著者 掲載種別：研究論文（学術雑誌）
-
Excess treatment reduction including anthracyclins results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. 査読あり
Tomizawa D., Tawa A., Watanabe T., Saito AM, Kudo K., Taga T, Iwamoto S., Shimads A., Terui K., Moritake H., Kinoshita A., Takahashi H., Nakayama H., Koh K., KIgasawa H., Kosaka Y., Miyachi H., Horibe K., Nakahata T., Adachi S
Leukemia 27 ( 12 ) 2413 - 2416 2013年12月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group 査読あり
Tomizawa D., Tawa A., Watanabe T., Saito AM, Kudo K., Taga T, Iwamoto S., Shimads A., Terui K., Moritake H., Kinoshita A., Takahashi H., Nakayama H., Kiyokawa N., Isoyama K., MIzutani S., Hara J., Horibe K., Nakahata T., Adachi S
Int J Hematol 98 ( 5 ) 578 - 588 2013年11月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Ewing Sarcoma Cells Secrete EWS/Fli-1 Fusion mRNA via Microvesicles 査読あり
Tsugita M., Yamada N., Noguchi S., Yamada K., Moritake H., Shimizu K., Akao Y., Ohno T.
PLoS ONE 8 ( 10 ) 2013年10月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：PLoS ONE
Tumours defined as Ewing sarcoma (ES) constitute a group of highly malignant neoplasms that most often affect children and young adults in the first 2 decades of life. The EWS/Fli-1 fusion gene, a product of the translocation t(11;22) (q24; 12), is detected in 95% of ES patients. Recently, it was validated that cells emit a heterogeneous mixture of vesicular, organelle-like structures (microvesicles, MVs) into their surroundings including blood and body fluids, and that these MVs contain a selected set of tumor-related proteins and high levels of mRNAs and miRNAs. In this present study, we detected the Ewing sarcoma-specific EWS/Fli-1 mRNA in MVs from the culture medium of ES cell lines carrying t(11;22) (q24; 12). Also, we detected this fusion gene in approximately 40% of the blood samples from mice inoculated with xenografts of TC135 or A673 cells. These findings indicate the EWS/Fli-1 mRNA in MVs might be a new non-invasive diagnostic marker for specific cases of Ewing sarcoma. © 2013 Tsugita et al.
-
深在性真菌感染症に腫瘍関連血球貪食症候群を合併した難治性急性骨髄性白血病 査読あり
山田 愛, 盛武 浩, 澤 大介, 下之段 秀美, 児嶋 ひとみ, 上村 幸代, 布井 博幸
臨床血液 54 ( 4 ) 383 - 387 2013年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：The Japanese Society of Hematology
症例は2歳女児。髄外浸潤を伴うMLL遺伝子再構成陽性急性骨髄性白血病(AML)を発症した。MLL遺伝子の融合相手としてMLLT10を分離した。治療終了2ヵ月後に骨髄と中枢神経系の複合再発をきたし，再寛解導入療法を施行するも血球貪食症候群(HLH)と侵襲性肺アスペルギルス症(IPA)を合併した。抗真菌剤投与で感染コントロール良好となってもHLHは改善せず，骨髄生検検体でMLL-MLLT10遺伝子が検出され，白血病幹細胞(LSC)の残存による腫瘍関連HLHと考えた。ゲムツズマブ・オゾガマイシンやソラフェニブを使用したが寛解は得られず，原疾患，HLH, IPAの悪化にて永眠した。AMLの再発は，LSCの特殊な分裂周期により従来の抗がん剤への抵抗性を示すことが要因とされる。本症例で様々な化学療法を用いても再寛解導入不応であったのはLSC残存の可能性が考えられた。今後LSCを標的とした治療の開発が望まれる。
-
小児急性前骨髄球性白血病に対する三酸化ヒ素による治療 査読あり
高橋浩之、盛武 浩、照井君典、井上彰子、落合秀匡、金井理恵、豊田秀実、松野良介、塩原正明、中尾朋平、富澤大輔、多賀崇、多和昭雄、足立壮一
日本小児血液・がん学会誌 50 ( 1 ) 32 - 37 2013年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Yamada A., Moritake H., Sawa D., Shimonodan H., Kojima H., Kamimura S., Nunoi H.
[Rinshō ketsueki] The Japanese journal of clinical hematology 54 ( 4 ) 383 - 387 2013年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：[Rinshō ketsueki] The Japanese journal of clinical hematology
We here report a 2-year-old female with relapsed acute myeloid leukemia (AML) with MLL gene rearrangement in the bone marrow and central nervous system. The 3'-RACE (Rapid Amplification of cDNA Ends) method identified the MLLT10 gene as a fusion partner of the MLL gene. The patient was complicated with hemophagocytic lymphohistiocytosis (HLH) and invasive aspergillosis (IPA) after re-induction treatment with FLAG-IDA following etoposide, cytarabine, and mitoxantrone. Although treatment with systemic anti-fungal drugs was effective for IPA, HLH did not improve. We considered tumor-associated HLH to be initiated from leukemic stem cells (LSCs) in the bone marrow niche because reverse transcription-polymerase chain reaction (RT-PCR) analysis of a bone marrow biopsy sample was positive for MLL-MLLT10. Gemtuzumab ozogamicin and sorafenib had no major effect on acquiring complete remission, and the patient died of progressive AML with an exacerbation of HLH and aspergillosis. LSCs are known to be resistant to conventional chemotherapy due to their quiescence in the cell cycle. Novel therapeutic concepts are important to eradicate LSCs in order to cure AML patients.
-
Boron neutron capture therapy (BNCT) selectively destroys human clear cell sarcoma in mouse model 査読あり
Fujimoto T., Andoh T., Sudo T., Fujita I., Moritake H., Sugimoto T., Sakuma Y., Akisue T., Kawabata S., Kirihara M., Suzuki M., Sakurai Y., Ono K., Fukumori Y., Kurosaka M., Ichikawa H.
Applied Radiation and Isotopes 73 96 - 100 2013年3月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice 査読あり
Yamada K., Ohno T., Aoki H., Semi K., Watanabe A., Moritake H., Shiozawa S., Kunisada T., Kobayashi Y., Toguchida J., Shimizu K., Hara A., Yamada Y.
Journal of Clinical Investigation 123 ( 2 ) 600 - 610 2013年2月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Clinical Investigation
Clear cell sarcoma (CCS) is an aggressive soft tissue malignant tumor characterized by a unique t(12;22) translocation that leads to the expression of a chimeric EWS/ATF1 fusion gene. However, little is known about the mechanisms underlying the involvement of EWS/ATF1 in CCS development. In addition, the cellular origins of CCS have not been determined. Here, we generated EWS/ATF1-inducible mice and examined the effects of EWS/ATF1 expression in adult somatic cells. We found that forced expression of EWS/ATF1 resulted in the development of EWS/ATF1-dependent sarcomas in mice. The histology of EWS/ATF1-induced sarcomas resembled that of CCS, and EWS/ATF1-induced tumor cells expressed CCS markers, including S100, SOX10, and MITF. Lineage-tracing experiments indicated that neural crest-derived cells were subject to EWS/ATF1-driven transformation. EWS/ATF1 directly induced Fos in an ERK-independent manner. Treatment of human and EWS/ATF1-induced CCS tumor cells with FOS-targeted siRNA attenuated proliferation. These findings demonstrated that FOS mediates the growth of EWS/ATF1-associated sarcomas and suggest that FOS is a potential therapeutic target in human CCS.
DOI： 10.1172/JCI63572
-
Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia 査読あり
Moritake H, Kamimura S, Kojima H, Shimonodan H, Harada M, Sugimoto T, Nao-I N, Nunoi H
Pediatr Blood Cancer 60 ( 2 ) 329 - 331 2013年2月
担当区分：筆頭著者 掲載種別：研究論文（学術雑誌）
-
Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia. 査読あり
Moritake H.＊, Kamimura S., Kojima H., Shimonodan H., Harada M., Sugimoto T., Nao-I N., Nunoi H
Pediatric Blood and Cancer 60 ( 2 ) 329 - 331 2013年2月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
小児がん経験者の病気のとらえ方の特徴と退院後の生活における困難との関連 査読あり
武井 優子, 尾形 明子, 小澤 美和, 盛武 浩, 平井 啓, 真部 淳, 鈴木 伸一
行動療法研究 = Japanese journal of behavior therapy 39 ( 1 ) 23 - 33 2013年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人日本認知・行動療法学会
本研究の目的は、小児がん患者の病気に対するとらえ方の特徴と、それらが患者の心理社会的問題や適応とどのような関連があるのかを検討することであった。小児科外来通院中の21名の小児がん患者を対象に半構造化面接を実施し、病気に対するとらえ方と退院後の生活における困難について聴取した。また、健康関連QOL尺度(Peds-QL)を測定した。Fisherの直接確率検定の結果、退院後の生活で経験する困難が病気のとらえ方に影響を及ぼしている可能性が示唆された。また、重回帰分析の結果、前向きなとらえ方がQOLに正の影響を、後ろ向きなとらえ方やあきらめの姿勢が負の影響を及ぼす様相が示唆されたが、統計的には有意ではなかった。今後は、対象者数を増やし、量的検討を実施していく必要がある。
-
Efficacy of Temozolomide in a Central Nervous System Relapse of Neuroblastoma with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation 査読あり
Yamada A., Moritake H.＊, Shimonodan H., Yokogami K., Takeshima H., Nunoi H
Journal of Pediatric Hematology and Oncology 35 ( 1 ) e38 - e41 2013年1月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
小児非ホジキンリンパ腫の治療成績 : 九州・山口小児がん研究グループKYCCSG NHL-89, 96 査読あり
深野 玲司, 住江 愛子, 松崎 彰信, 稲田 浩子, 永利 義久, 石井 榮一, 中山 秀樹, 川上 清, 盛武 浩, 柳井 文男, 糸長 伸能, 末延 聡一, 菊池 昌弘, 岡村 純, 河野 嘉文
臨床血液 53 ( 11 ) 1898 - 1905 2012年11月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：The Japanese Society of Hematology
KYCCSGでは1989年から小児NHLに対して継続する二つの治療研究NHL-89, NHL-96を施行した。当時，小児NHLはdiffuse large cell lymphoma (DLC), lymphoblastic lymphoma (LBL), small non-cleaved lymphomaの組織型に分類されており，本研究ではDLC, LBLを対象とした。NHL-89に42例（DLC: 15例，LBL: 27例），NHL-96に34例（DLC: 8例，LBL: 26例）が登録された。DLCにはMTX大量投与を含む寛解導入療法後に，MTX中等量投与を反復した。LBLにはPSL, VCR, CPM, ADR (THP-ADR)による寛解導入療法後に強化療法，頭蓋照射を含むCNS再発予防を行い，維持療法はPSL, VCR, CPM, 6-MPなどによる多剤でのブロック治療とした。全体の5年EFSはNHL-89が76.2±6.6％，NHL-96が67.7±8.0％であり，過去の治療研究NHL-858と比較して成績の向上に成功した。